Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges |
| |
Authors: | Wang Danher Hevey Michael Juompan Laure Y Trubey Charles M Raja Nicholas U Deitz Stephen B Woraratanadharm Jan Luo Min Yu Hong Swain Benjamin M Moore Kevin M Dong John Y |
| |
Institution: | Division of Bio-defense Vaccines, GenPhar Inc., 871 Lowcountry Blvd., Mount Pleasant, SC 29464, USA. |
| |
Abstract: | The Marburg virus (MARV), an African filovirus closely related to the Ebola virus, causes a deadly hemorrhagic fever in humans, with up to 90% mortality. Currently, treatment of disease is only supportive, and no vaccines are available to prevent spread of MARV infections. In order to address this need, we have developed and characterized a novel recombinant vaccine that utilizes a single complex adenovirus-vectored vaccine (cAdVax) to overexpress a MARV glycoprotein (GP) fusion protein derived from the Musoke and Ci67 strains of MARV. Vaccination with the cAdVaxM(fus) vaccine led to efficient production of MARV-specific antibodies in both mice and guinea pigs. Significantly, guinea pigs vaccinated with at least 5 x 10(7) pfu of cAdVaxM(fus) vaccine were 100% protected against lethal challenges by the Musoke, Ci67 and Ravn strains of MARV, making it a vaccine with trivalent protective efficacy. Therefore, the cAdVaxM(fus) vaccine serves as a promising vaccine candidate to prevent and contain multi-strain infections by MARV. |
| |
Keywords: | Marburg virus Vaccine cAdVax Glycoprotein Challenge Musoke Ravn Ci67 |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|